# The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

> **NCT04212598** · PHASE2 · COMPLETED · sponsor: **Wuhan University** · enrollment: 40 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04212598
- **Lead sponsor:** Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-03
- **Primary completion:** 2024-11-03
- **Final completion:** 2024-11-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04212598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04212598, "The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04212598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*